UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy

Biochemical pharmacology, 2022-03, Vol.197, p.114899-114899, Article 114899

2022

Volltextzugriff (PDF)

Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo

Scientific reports, 2018-01, Vol.8 (1), p.1552-18, Article 1552

2018

Volltextzugriff (PDF)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes

Patient related outcome measures, 2022-05, Vol.13, p.97-111

2022

Volltextzugriff (PDF)

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Quality of life research, 2021-07, Vol.30 (7), p.2033-2043

2021

Volltextzugriff (PDF)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data

Diabetes therapy, 2019-06, Vol.10 (3), p.1067-1088

2019

Volltextzugriff (PDF)

PDB39 Dosing Patterns Among Patients with Type 2 Diabetes (T2D) Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) in France and the Netherlands

Value in health, 2021-06, Vol.24, p.S84-S84

2021

Volltextzugriff (PDF)

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

The European journal of health economics, 2020-11, Vol.21 (8), p.1179-1196

2020

Volltextzugriff (PDF)

PDB34 The PRIME Type 2 Diabetes MODEL: A New, Product-Independent MODEL to Evaluate LONG-TERM Clinical and Cost Outcomes in Type 2 Diabetes

Value in health, 2020-12, Vol.23, p.S511-S511

2020

Volltextzugriff (PDF)

Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature

Advances in therapy, 2024-07, Vol.41 (7), p.2655-2681

2024

Volltextzugriff (PDF)

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

Current medical research and opinion, 2019-05, Vol.35 (5), p.893-901

2019

Volltextzugriff (PDF)

Deletion or inhibition of prolyl oligopeptidase blocks lithium‐induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A

Basic & clinical pharmacology & toxicology, 2021-10, Vol.129 (4), p.287-296

2021

Volltextzugriff (PDF)

POSB159 Comparing Modeled Outcomes with Published Studies in the Japanese Setting: A Validation Analysis with the Prime Type 2 Diabetes Model

Value in health, 2022-01, Vol.25 (1), p.S91-S91

2022

Volltextzugriff (PDF)

Trust, good governance and unethical actions in Finnish public administration

The International journal of public sector management, 2010-01, Vol.23 (7), p.647-668

2010

Volltextzugriff (PDF)

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

Pharmacological research, 2020-01, Vol.151, p.104558, Article 104558

2020

Volltextzugriff (PDF)

Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease

Journal of cellular and molecular medicine, 2019-12, Vol.23 (12), p.8511-8515

2019

Volltextzugriff (PDF)

PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

Value in health, 2018-10, Vol.21, p.S137-S137

2018

Volltextzugriff (PDF)

672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture

Neuroscience letters, 2017-01, Vol.636, p.83-89

2017

Volltextzugriff (PDF)

Prolyl oligopeptidase inhibition reduces alpha‐synuclein aggregation in a cellular model of multiple system atrophy

Journal of cellular and molecular medicine, 2021-10, Vol.25 (20), p.9634-9646

2021

Volltextzugriff (PDF)

The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus

Journal of medical economics, 2022-12, Vol.25 (1), p.393-402

2022

Volltextzugriff (PDF)

93-LB: Preferences and Health State Utilities Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK

Drugs in R&D, 2019-06, Vol.19 (2), p.213-225

2019

Volltextzugriff (PDF)

The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus

Value in health, 2017-07, Vol.20 (7), p.985-991

2017

Volltextzugriff (PDF)

Schémas thérapeutiques et posologiques chez des patients avec un diabète de type 2 (DT2) initiant un traitement par agoniste du récepteur du Glucagon-like peptide 1 (AR GLP-1) en Europe

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A35

2017

Volltextzugriff (PDF)

CO-92 - Schémas thérapeutiques et posologiques chez des patients avec un diabète de type 2 (DT2) initiant un traitement par agoniste du récepteur du Glucagon-like peptide 1 (AR GLP-1) en Europe

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A35-A35

2017

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(78)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy

Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data

PDB39 Dosing Patterns Among Patients with Type 2 Diabetes (T2D) Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) in France and the Netherlands

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

PDB34 The PRIME Type 2 Diabetes MODEL: A New, Product-Independent MODEL to Evaluate LONG-TERM Clinical and Cost Outcomes in Type 2 Diabetes

Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

Deletion or inhibition of prolyl oligopeptidase blocks lithium‐induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A

POSB159 Comparing Modeled Outcomes with Published Studies in the Japanese Setting: A Validation Analysis with the Prime Type 2 Diabetes Model

Trust, good governance and unethical actions in Finnish public administration

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease

PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis

Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture

Prolyl oligopeptidase inhibition reduces alpha‐synuclein aggregation in a cellular model of multiple system atrophy

The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus

93-LB: Preferences and Health State Utilities Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK

The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus

Schémas thérapeutiques et posologiques chez des patients avec un diabète de type 2 (DT2) initiant un traitement par agoniste du récepteur du Glucagon-like peptide 1 (AR GLP-1) en Europe

CO-92 - Schémas thérapeutiques et posologiques chez des patients avec un diabète de type 2 (DT2) initiant un traitement par agoniste du récepteur du Glucagon-like peptide 1 (AR GLP-1) en Europe

Suchergebnisse filtern